Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 3Dermatologic 2Breast 2Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Colorectal Neoplasms 5948Pancreatic Neoplasms 3563Carcinoma, Hepatocellular 3273Stomach Neoplasms 3057Colonic Neoplasms 2328Rectal Neoplasms 2192Esophageal Neoplasms 1801Liver Neoplasms 1247Neoplasms 1181Breast Neoplasms 1064Neoplasm Metastasis 871Carcinoma, Non-Small-Cell Lung 794Lung Neoplasms 745Cholangiocarcinoma 743Gastrointestinal Neoplasms 662Ovarian Neoplasms 630Esophageal Squamous Cell Carcinoma 585Prostatic Neoplasms 485Melanoma 457Biliary Tract Neoplasms 441Head and Neck Neoplasms 376Uterine Cervical Neoplasms 344Carcinoma, Renal Cell 329Gastrointestinal Stromal Tumors 326Adenocarcinoma Of Esophagus 315Sarcoma 304Barrett Esophagus 300Anus Neoplasms 284Gallbladder Neoplasms 283Endometrial Neoplasms 281

Interventions

zenocutuzumab 1enzalutamide 1Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Gastrointestinal × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Cancer Research UK

Phase 1/2 Active not recruiting
81 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Partner Therapeutics, Inc.

Phase 2 Active not recruiting
250 enrolled 2 FDA
GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡